Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Evaxion Biotech A/S - ADR - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
EVAX
Nasdaq
8731
https://www.evaxion-biotech.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Evaxion Biotech A/S - ADR
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
- Apr 17th, 2024 12:00 pm
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
- Apr 3rd, 2024 3:26 pm
Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call Transcript
- Apr 3rd, 2024 12:57 pm
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
- Apr 2nd, 2024 11:00 am
Evaxion Announces Business Update and Full Year 2023 Financial Results
- Mar 27th, 2024 11:30 am
When Will Evaxion Biotech A/S (NASDAQ:EVAX) Turn A Profit?
- Mar 22nd, 2024 11:10 am
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
- Mar 19th, 2024 11:30 am
Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations
- Feb 29th, 2024 12:30 pm
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
- Feb 20th, 2024 12:30 pm
Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Feb 7th, 2024 1:30 pm
Evaxion Announces Closing of $15 Million Public Offering
- Feb 6th, 2024 1:30 pm
Evaxion Biotech Announces Pricing of $15 Million Public Offering
- Feb 1st, 2024 2:20 pm
Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
- Jan 24th, 2024 1:30 pm
Evaxion Announces Completion of ADS Ratio Change
- Jan 22nd, 2024 9:30 pm
Evaxion Announces Plan to Implement ADS Ratio Change
- Jan 8th, 2024 1:30 pm
Evaxion Biotech Announces Closing of Private Placement
- Dec 21st, 2023 9:30 pm
Evaxion Announces Business Update and Third Quarter 2023 Financial Results
- Dec 19th, 2023 9:15 pm
Evaxion Biotech Announces Private Placement Financing
- Dec 19th, 2023 2:25 pm
Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept
- Nov 28th, 2023 1:27 pm
Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy
- Nov 15th, 2023 1:00 pm
Scroll